Golimumab Dosage
This dosage information may not include all the information needed to use Golimumab safely and effectively. See additional information for Golimumab.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Rheumatoid Arthritis
For the treatment of moderate to severe active rheumatoid arthritis in combination with methotrexate:
50 mg administered by subcutaneous (SC) injection once a month.
Usual Adult Dose for Ankylosing Spondylitis
50 mg administered by subcutaneous (SC) injection once a month.
May be given with or without methotrexate or other non biologic DMARDs (Disease-modifying antirheumatic drugs)
Usual Adult Dose for Psoriatic Arthritis
50 mg administered by subcutaneous (SC) injection once a month.
May be given with or without methotrexate or other non biologic DMARDs (Disease-modifying antirheumatic drugs)
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal, and other opportunistic infections have occurred in patients receiving golimumab.
Patients should be tested for latent tuberculosis before golimumab use and during therapy, even if initial latent TB test is negative. Treatment for latent infection should be initiated prior to golimumab use.
Invasive fungal infections have included histoplasmosis, coccidioidomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
Treatment should not be initiated in patients with an active infection, including clinically important localized infections. The risks and benefits of treatment should be considered prior to initiating treatment in patients with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment. Treatment should be discontinued if a patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment should undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
Other Comments
Corticosteroids, non biologic DMARDs, and/or NSAIDs may be continued during treatment with golimumab.
